[Ed. Note: Dr. KSS writes about medicine and biotech for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. Enjoy!] Conclusion of a Series on Pain [This column is dedicated to recovery from a recent cancer diagnosis of a stuff-of-legend friend whose life I cherish. She recently […]
Articles
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
Let's be clear I've not read yet the Treasury dept new rulings about inversion deals. But I have to ask, and hope more l...
Alkerme´s (ALKS) drug for schizophrenia (Aristada) shows high efficacy. http://finance.yahoo.com/news/alkermes-arista...
While we've been bemoaning markets and Fed behavior, Irish Alkermes ($ALKS) has been in stealth rally mode since late Au...
An intersting point of view for you all: May 22, 2015, 1:12 P.M. ET Esperion Therapeutics: 15 Reasons to Take Profit...
Alkermes $ALKS will move a new entity ALK7119 into phase 1 for Alzheimer-related agitation in 3Q15. I am seeking clarifi...
Peter: in the neuropsych space, are you aware of any particular drugmakers that we should look into in January for 2015?...
Reiterating long buy sentiment on Dublin firm Alkermes ($ALKS), with which I am well in the black (or green depending on...
Hi isabelle: I still like the company and am long in shares of it. Their psychiatry drug portfolio is solid and self-ass...
Anyone have an opinion on Alkermes (ALKS)? I know we talk mostly about microcaps here and they are far from that, but t...